Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Opthea.
RELATED STOCKHEAD STORIES
Health & Biotech
Broker Upgrades: Canaccord says disease specialist Opthea could triple if Phase III trial passes muster
Health & Biotech
Phase III Trials: It’s crunch time for these ASX health stocks
Health & Biotech
Scott Power: Cardiac pacing device developer EBR hits Morgans price target amid ‘rotation back into healthcare’
Health & Biotech
Health Check: New JV for Opyl; Dimerix inks another licensing deal
Health & Biotech
Health Check: Local biotech starred in 2024, but the rising tide did not lift all boats
Health & Biotech
Stocking stuffers: Morgans’ top ASX health picks for 2025
Health & Biotech
Health Check: It’s a wipe out! Percheron shares tumble up to 91pc on rare genetic disease trial failure
Health & Biotech
Health Check: Can Syntara produce the next multibillion-dollar Aussie blood cancer drug?
Health & Biotech
Health Check: It’s a small world after all for global microcap index additions LTR Pharma and EZZ Life Science
Health & Biotech
Health Check: Medical pot play Cann Group sees an earnings turnaround through the haze
News
Market Highlights: Wall Street spooked after Powell warns not to get too excited; and 5 small caps to watch
News
ASX Rebalance: Copper in, lithium out as hot biotechs climb ranks
Health & Biotech
Alive and Kicking: ‘We are not alone in going through a lull in markets’, says Clinuvel chair
Health & Biotech
Bio Curious: How Dimerix negotiates the ‘valleys of death’ on the winding road to drug approval
Investor Guides
Investor Guide: Health & Biotech FY2025 featuring Tim Boreham
News
Closing Bell: Local tech talent steps up ahead of blockbuster inflation week
News
